{"id":"https://openalex.org/W2020684204","doi":"https://doi.org/10.1007/s00280-014-2616-4","title":"Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing","display_name":"Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing","publication_year":2014,"publication_date":"2014-10-24","ids":{"openalex":"https://openalex.org/W2020684204","doi":"https://doi.org/10.1007/s00280-014-2616-4","mag":"2020684204","pmid":"https://pubmed.ncbi.nlm.nih.gov/25344090"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-014-2616-4","doi":"https://doi.org/10.1007/s00280-014-2616-4","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-014-2616-4","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Kouichi Inoue","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265673","display_name":"Janssen Pharmaceutical K.K. (Japan)","ror":"https://ror.org/05eqqvk78","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405265673"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kouichi Inoue","raw_affiliation_strings":["Janssen Pharmaceutical, KK, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Pharmaceutical, KK, Tokyo, Japan","institution_ids":["https://openalex.org/I4405265673"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Akira Shishido","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265673","display_name":"Janssen Pharmaceutical K.K. (Japan)","ror":"https://ror.org/05eqqvk78","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405265673"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akira Shishido","raw_affiliation_strings":["Janssen Pharmaceutical, KK, Tokyo, Japan","Janssen Pharmaceutical, KK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Pharmaceutical, KK, Tokyo, Japan","institution_ids":["https://openalex.org/I4405265673"]},{"raw_affiliation_string":"Janssen Pharmaceutical, KK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108500272","display_name":"Nicole M. Vaccaro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicole Vaccaro","raw_affiliation_strings":["Janssen Research and Development, LLC, Titusville, USA","Janssen Research and Development, LLC.;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development, LLC, Titusville, USA","institution_ids":[]},{"raw_affiliation_string":"Janssen Research and Development, LLC.;","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109192593","display_name":"James Juhui Jiao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Jiao","raw_affiliation_strings":["Janssen Research and Development, LLC, Titusville, USA","Janssen Research and Development, LLC.;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development, LLC, Titusville, USA","institution_ids":[]},{"raw_affiliation_string":"Janssen Research and Development, LLC.;","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076233215","display_name":"Hans Stieltjes","orcid":"https://orcid.org/0009-0006-6913-7285","observed_orcids":["https://orcid.org/0009-0006-6913-7285"]},"institutions":[{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Hans Stieltjes","raw_affiliation_strings":["Janssen Research and Development (a Division of Janssen Pharmaceutica), NV, Beerse, Belgium","Janssen Research and Development, a division of Janssen Pharmaceutica NV"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development (a Division of Janssen Pharmaceutica), NV, Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Janssen Research and Development, a division of Janssen Pharmaceutica NV","institution_ids":["https://openalex.org/I137982388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028032107","display_name":"Apexa Bernard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Apexa Bernard","raw_affiliation_strings":["Janssen Research and Development, LLC, Titusville, USA","Janssen Research and Development, LLC.;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development, LLC, Titusville, USA","institution_ids":[]},{"raw_affiliation_string":"Janssen Research and Development, LLC.;","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103094893","display_name":"Margaret K. Yu","orcid":"https://orcid.org/0009-0003-1697-3595","observed_orcids":["https://orcid.org/0009-0003-1697-3595","https://orcid.org/0000-0002-3650-2788"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Margaret Yu","raw_affiliation_strings":["Janssen Research and Development, LLC, Titusville, USA","Janssen Research and Development, LLC.;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development, LLC, Titusville, USA","institution_ids":[]},{"raw_affiliation_string":"Janssen Research and Development, LLC.;","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112820492","display_name":"Caly Chien","orcid":"https://orcid.org/0009-0002-7054-9536","observed_orcids":["https://orcid.org/0009-0002-7054-9536"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Caly Chien","raw_affiliation_strings":["Janssen Research and Development, LLC, Titusville, USA","Janssen Research and Development, LLC.;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development, LLC, Titusville, USA","institution_ids":[]},{"raw_affiliation_string":"Janssen Research and Development, LLC.;","institution_ids":["https://openalex.org/I4405282460"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5112820492"],"corresponding_institution_ids":["https://openalex.org/I4405282460"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":null,"fwci":0.6919,"has_fulltext":false,"cited_by_count":17,"citation_normalized_percentile":{"value":0.64515522,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"75","issue":"1","first_page":"49","last_page":"58"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9761000275611877,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9761000275611877,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.010900000110268593,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/abiraterone-acetate","display_name":"abiraterone","score":0.996999979019165},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.996999979019165},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.8920000195503235},{"id":"https://openalex.org/keywords/meal-timing","display_name":"meal timing","score":0.9509999752044678},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.8579999804496765},{"id":"https://openalex.org/keywords/single-dose-administration","display_name":"single-dose administration","score":0.875},{"id":"https://openalex.org/keywords/drug-exposure","display_name":"drug exposure","score":0.4169999957084656},{"id":"https://openalex.org/keywords/ethnic-differences","display_name":"ethnic differences","score":0.5640000104904175}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8615460991859436},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8322867155075073},{"id":"https://openalex.org/C2776421732","wikidata":"https://www.wikidata.org/wiki/Q27888393","display_name":"Abiraterone","level":5,"score":0.6702769994735718},{"id":"https://openalex.org/C2775832370","wikidata":"https://www.wikidata.org/wiki/Q27888393","display_name":"Abiraterone acetate","level":5,"score":0.5762553215026855},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5684476494789124},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.5425030589103699},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.44422146677970886},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4265557825565338},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.419990599155426},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3983273506164551},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.36686792969703674},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2092452049255371},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.0},{"id":"https://openalex.org/C2777899217","wikidata":"https://www.wikidata.org/wiki/Q4759439","display_name":"Androgen deprivation therapy","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000069501","descriptor_name":"Abiraterone Acetate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000736","descriptor_name":"Androstenes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000736","descriptor_name":"Androstenes","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000736","descriptor_name":"Androstenes","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D000736","descriptor_name":"Androstenes","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001213","descriptor_name":"Asian","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":"Q000208","qualifier_name":"ethnology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008657","descriptor_name":"Metabolic Clearance Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011471","descriptor_name":"Prostatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D011471","descriptor_name":"Prostatic Neoplasms","qualifier_ui":"Q000208","qualifier_name":"ethnology","is_major_topic":false},{"descriptor_ui":"D013254","descriptor_name":"Steroid 17-alpha-Hydroxylase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018565","descriptor_name":"Food-Drug Interactions","qualifier_ui":"Q000208","qualifier_name":"ethnology","is_major_topic":true},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018931","descriptor_name":"Antineoplastic Agents, Hormonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018931","descriptor_name":"Antineoplastic Agents, Hormonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018931","descriptor_name":"Antineoplastic Agents, Hormonal","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D018931","descriptor_name":"Antineoplastic Agents, Hormonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D044465","descriptor_name":"White People","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D062407","descriptor_name":"Meals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065607","descriptor_name":"Cytochrome P-450 Enzyme Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D065607","descriptor_name":"Cytochrome P-450 Enzyme Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D065607","descriptor_name":"Cytochrome P-450 Enzyme Inhibitors","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D065607","descriptor_name":"Cytochrome P-450 Enzyme Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1007/s00280-014-2616-4","doi":"https://doi.org/10.1007/s00280-014-2616-4","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-014-2616-4","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmid:25344090","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25344090","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W287999946","https://openalex.org/W1561231235","https://openalex.org/W1954415024","https://openalex.org/W1970172077","https://openalex.org/W1993832391","https://openalex.org/W2005446347","https://openalex.org/W2012524759","https://openalex.org/W2015014216","https://openalex.org/W2021775978","https://openalex.org/W2030975106","https://openalex.org/W2034615747","https://openalex.org/W2060134937","https://openalex.org/W2074026346","https://openalex.org/W2086869114","https://openalex.org/W2110534364","https://openalex.org/W2113569308","https://openalex.org/W2128301586","https://openalex.org/W2133099372","https://openalex.org/W2137467802","https://openalex.org/W2147018237","https://openalex.org/W2161817637","https://openalex.org/W2170544517","https://openalex.org/W2221617539"],"related_works":["https://openalex.org/W2724981648","https://openalex.org/W2972634291","https://openalex.org/W2015014216","https://openalex.org/W2103407911","https://openalex.org/W7096082324","https://openalex.org/W3080986409","https://openalex.org/W2591552977","https://openalex.org/W2768693657","https://openalex.org/W2598617552","https://openalex.org/W4385798348"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}